Forbes  9 hrs ago  Comment 
Despite an expected dip in profit, analysts are generally optimistic about Novartis as it prepares to reports its second-quarter earnings on Tuesday, July 21, 2015. The consensus earnings per share estimate is $1.20 per share.Despite not changing...
newratings.com  Jul 16  Comment 
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients Novartis International AG / Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access...
FiercePharma  Jul 13  Comment 
The launch for Glatopa, the new generic of Teva's Copaxone from Novartis' Sandoz, is still in the very early going. But so far, things look good--very good.
The Economic Times  Jul 13  Comment 
India has cleared a host of foreign investment proposals including Glaxo SmithKline, Novartis, Mylan, Catholic Syrian Bank and Bandhan Financial Services.
Market Intelligence Center  Jul 13  Comment 
After Friday’s trading in Novartis AG (NVS) the option-trade picking algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center uncovered a trade that offers a 2.44% return, or 9.37% annualized (for comparison purposes...
The Hindu Business Line  Jul 10  Comment 
Drug major Sandoz will discontinue operations at its Turbhe site (Maharashtra) by end December 2016, as part of global plans to optimise its manufacturing network.The Turbhe sites em...
FiercePharma  Jul 10  Comment 
Novartis has said it's planning to offer an outcomes-based plan for its new blockbuster-in-the-making to secure payers' favor. But skeptics see some kinks in the plan--and the CMO at leading PBM Express is one of them.
Wall Street Journal  Jul 10  Comment 
Novartis AG might offer a bundle of health-care services alongside its promising new heart-failure drug to win over increasingly cost-conscious insurers, its chief executive said.
Benzinga  Jul 9  Comment 
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, today announced it has launched its seventh product, diclofenac sodium 1.5% topical solution, after receipt of the final approval from the U.S....


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki